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Abstract
Objective: To determine effects of probiotic consumption on clinical and immunological parameters of seasonal allergic
rhinitis (SAR) in an out-of-season single nasal allergen challenge.
Methods: In a study registered at ClinicalTrials.Gov (NCT01123252), a 16-week dietary intervention was undertaken in 60
patients with allergic rhinitis (.16 years old). Using a double-blinded, placebo-controlled anonymised design, the patients
were divided equally into two groups. One group was given a dairy drink containing Lactobacillus casei Shirota to ingest
daily while the other consumed a similar drink without bacteria. Participants attended the clinic on two consecutive days
before the intervention and then again at the end of the study period. On the first day of each 2-day visit, following clinical
examination, assessments were made of total nasal symptoms scores and peak nasal inspiratory flow. Nasal scrapings, nasal
lavage and blood were collected for laboratory analyses of cellular phenotypes, soluble mediator release and in vitro
responses to pollen allergen. These procedures were repeated 24 hours following nasal allergen challenge.
Results: Prior to and following intervention there were no detectable differences between study groups in measured clinical
outcome. After intervention, there were differences between groups in their percentages of CD86+ epithelial cells
(p= 0.0148), CD86+CD252+ non-epithelial cells (p= 0.0347), sIL-1RII release (p= 0.0289) and IL-1b (p= 0.0224) levels at the
nasal mucosa. Delivery of probiotic also suppressed production of sCD23 (p= 0.0081), TGF-b (p= 0.0283) and induced
increased production of IFN-c (p= 0.0351) in supernatants of cultured peripheral blood.
Conclusions & Clinical Relevance: This study did not show significant probiotic-associated changes with respect to the
primary clinical endpoint. An absence of overt clinical benefit may be due to an inability of single nasal challenges to
accurately represent natural allergen exposure. Nevertheless, oral delivery of probiotics produced changes of the
immunological microenvironment at the nasal mucosa in individuals affected by SAR.
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Introduction
Epidemiological studies and recent experimental research
support the idea that microbial stimulation of the immune system
can influence development of tolerance to innocuous allergens [1].
This makes the gastrointestinal microbiota composition of
particular interest, as it provides a major source of immune
stimulation and that seems to be a prerequisite for the
development of oral tolerance. In allergic diseases, there is thought
to be a dysregulation in the expression of T helper 1 (Th1) and T
helper 2 cytokines (Th2) which can be alleviated to some extent by
Lactobacilli belonging to the natural intestinal microflora. One of
the proposed mechanisms for this includes direct interaction of
Lactobacilli with epithelial cells to modify their production of
inflammatory mediators [2].In a study of patients with allergic
rhinitis out of the pollen season, 4 weeks’ treatment with L. casei
reduced the number of CD16/CD56 cells, L. plantarum decreased
production of IL-5 and IL-13 and both probiotics reduced the
amount of birch-pollen specific IgE [3]. However, in this study
immune parameters were determined in serum and peripheral
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blood mononuclear cell cultures and the patients were not exposed
to allergen, which makes it impossible to evaluate the impact of
these findings on allergic disease. In our previous study involving
patients with allergic rhinitis receiving L casei Shirota (LcS) or
placebo for 5 months, we found a significant reduction in levels of
antigen-induced IL-5, IL-6 and IFN-gamma production during
the pollen season in the probiotic compared with placebo
supplemented group. Meanwhile, serum levels of specific IgG
increased and IgE decreased in the probiotic group [4].
Several trials have investigated the clinical benefit of adminis-
tering probiotic drinks to patients with seasonal allergic rhinitis [5]
(SAR). The available data are inconclusive and often contradictory
[6,7,8]. We have therefore conducted a double-blinded, placebo-
controlled study to test our hypothesis that daily consumption of
LcS over a period of four months will result in clinical
improvement in an allergen challenge model of allergic rhinitis,
with corresponding immunological changes at the nasal mucosa
and in blood. There are specific difficulties associated with clinical
trials in allergic rhinitis, such as variations between subjects in the
extent of pollen sensitization due to differences in exposure to
pollen. In order to control such variability we have used a single-
dose allergen challenge in the clinic. Total Nasal Symptom Score
(TNSS) was selected as the primary end-point because the nasal
symptom questionnaire is a convenient, reliable and valid method
for assessing nasal symptom severity. Its principal use was to act as
a primary outcome measure by comparing scores before and after
treatment. Secondary end-points included peak nasal inspiratory
flow (PNIF) as a simple, objective measurement of nasal airflow
and laboratory tests for local and systemic parameters of
immunity.
Materials and Methods
CONSORT checklist and the protocol for this trial are
available as supporting information; see Checklist S1 and Protocol
S1.
Ethics
The study protocol was approved by the local Institute of Food
Research Human Research Governance Committee (HRGC
ref:IFR05/2009) and national Hertfordshire Research Ethics
Committee NREC (ref:09/H0311/77). All subjects gave written,
informed consent before participating in the study.
Probiotic and placebo drinks
All drinks were supplied by Yakult Europe B.V. with HACCP
certification for the safety of materials, production process and
microbiological analysis (issued by Nederlandse Organisatie voor
Toegepast Natuurwetenschappelijk Onderzoek, the Netherlands).
The probiotic and placebo drinks were identical in packaging,
appearance and composition, except for the presence of 6.5610‘9
LcS per 65 ml bottle of probiotic drink. Participants were supplied
with refrigerated drinks every two weeks throughout the 4-month
intervention period. Compliance was monitored through recovery
of unused drinks at each delivery period.
Study Design
This was a randomised, double-blind, placebo-controlled trial
comparing the probiotic strain LcS with placebo in patients with
SAR. The study was conducted out of the grass pollen season,
between 11 September 2010 and 1 April 2011 (see Protocol S1 for
details of subject selection and randomisation) in accordance with
Good Clinical Practice including Research Ethics Committee (07/
MRE05/45) approval and all participants gave written informed
consent. The study was conducted according to the principles
expressed in the Declaration of Helsinki. At first, procedures were
undertaken to establish eligibility for recruitment to the study
(described below). Following this, pre-intervention baseline mea-
surements were made to document the intensity of local and
systemic responses of each patient to a nasal allergen (pollen)
challenge (NAC). At this time, patients were randomly allocated to
either group A or group B by the study statistician, according to
computer-generated randomisation code and given probiotic or
placebo drink to consume daily. After 16 weeks each patient
returned for post-intervention follow-up measurements.
Subject Selection and Randomisation
Sixty volunteers with SAR to Timothy Grass pollen were
recruited following screening for eligibility. Randomisation was
performed by the study statistician using a computer generated
code. Patients were randomised in blocks of 4 and 6 on a 1:1 ratio
with stratification for the presence/absence of asthma and
presence/absence of allergy to tree pollen to receive 65 ml
fermented milk drink containing 10‘9 Lactobacillus casei Shirota per
ml or similar milk drink without Lactobacillus casei Shirota.
Study Visits and Measurements
At least 2 weeks following the screening visit, subjects returned
for baseline assessments which consisted of measurements and
sample acquisition before, and 24 hours following a single-dose
nasal allergen challenge. Following clinical examination, baseline
total nasal symptom scores (TNSS) and peak nasal inspiratory flow
(PNIF) were obtained in all patients on a 4-point Likert scale
(0 = no symptoms, 3 =maximum symptoms). Patients with asthma
underwent spirometry using a Microlab spirometer (Micro
Medical Ltd, Rochester, Kent, UK) as per American Thoracic
Society/European Respiratory Society guidelines [9] and record-
ed their total asthma symptom scores. Subjects then underwent an
incremental nasal allergen challenge as described by Dreskin et al.
[10] using Timothy grass (ALK-Abello Ltd, Hungerford, Berk-
shire, UK) [9]. This was performed to find the dose for individual
study participants at which maximum symptoms occurred and
which would then be used as the challenging dose in the study
itself. Blood was taken for laboratory analyses. Nasal lavage was
performed according to the method described by Gru¨nberg et al.
[11] One to two nasal mucosal scrapes were obtained using a
Rhino-probe curette (Arlington Scientific Inc., Springville, Utah,
USA) according to the manufacturer’s instructions.
A single-dose nasal allergen challenge was undertaken using the
concentration of allergen which approximated a TNSS of 4 during
the incremental nasal allergen challenge. Nasal symptoms
(described above) and PNIF (measured in duplicate) were recorded
at 5, 10 and 30 minutes then hourly for 12 hours following the
challenge. Patients with asthma recorded asthma symptoms,
forced expiratory volume in 1 second (FEV1) and peak expiratory
flow (PEF) at 5, 10, 30 and 60 minutes following the nasal allergen
challenge. Nasal lavage was obtained 30 minutes following the
challenge in all patients who then returned to the clinic 24 hours
later for nasal symptom scoring, PNIF, blood sampling, nasal
lavage and nasal mucosal scraping, plus asthma symptom scoring
and spirometry for asthmatic patients.
The procedures were repeated identically after the patients had
received 16 weeks of study intervention. Post-intervention
assessments were made no later than March for participants with
grass and tree pollen allergy and no later than April for those with
isolated grass pollen allergy. (For detailed description see Protocol
S1).
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Laboratory Analyses
Nasal lavages were collected as described above and frozen in
dry ice immediately. Samples were then stored at 280uC and
thawed prior to testing, Lavage volumes were noted at each time
point and accounted for during analyses. Data for Eotaxin, IL-13,
IL-1b, IL-4, IL-5, MIP-1a and RANTES were acquired by flow
cytometry using a 7-plex cytometric bead array configuration
(Becton Dickinson, Oxford, UK). TSLP was measured as a bead-
based assay using Luminex instrumentation (Millipore UK Ltd,
Watford, UK).
Nasal scrapes were cultured for 48 hours in Airway Epithelial
Cell Growth Medium (Promocell, Heidelberg, Germany). Culture
supernatants were removed and stored at280uC for soluble factor
tests. The soluble cytokine receptors sCD30, sIL-1RI, sIL-4R, sIL-
IRII and sTNFR1 were analysed using Milliplex multi-analyte
profiling technology for Luminex instrumentation (Millipore UK
Ltd, Watford, UK). After removal of supernatants, adherent and
non-adherent cells were taken from culture, disaggregated and
permeabilized before staining with fluorochrome-labelled antibod-
ies. Cell surface CD86 (eBiosciences, Hatfield, UK), CD252
(Biolegend, London, UK) and intracellular cytokeratin (Beckman
Coulter, High Wycombe, UK) expression were documented by
flow cytometry (Beckman Coulter FC500-MPL cytometer).
Peripheral blood mononuclear cells (PBMNC) were derived
from heparinised blood by density gradient centrifugation. Isolated
cells were cultured at 37uC, 5% CO2 in air for 6 days in the
absence or presence of Timothy grass pollen (phleum pratense,
Phadia AB, Uppsala, Sweden). After this period culture superna-
tants were removed, aliquoted and frozen at 280uC for detection
of soluble molecules. IL-4, IL-5, IL-8, IL-10, IL-12p70, IL-13,
IFN-c, TNF-a, Eotaxin, MIP-1a and RANTES were analysed as
a multiplex cytometric bead array. TGF-b needed to be tested on
its own. All kits were purchased from BD Biosciences, Oxford, UK
and data acquired by flow cytometry (Beckman Coulter FC500
MPL instrument, UK). Soluble CD23 (sCD23; Life Technologies
Ltd, Paisley, UK) was quantified by ELISA.
Serum was separated from blood, frozen shortly after collection
and stored at 280C until used. Pollen-specific IgG, IgG4 and IgE
were quantified using the Pharmacia ImmunoCAP 100 system.
Statistical analysis
The primary clinical end-point was the TNSS at 10 minutes
following a single-dose nasal allergen challenge. A sample size of
46 participants was calculated to provide 90% power to detect a
treatment difference at a two-sided 5% significance level, if the
true difference between the treatments is a TNSS of 1.5 following
allergen challenge assuming a standard deviation of 1.5 [10].
Secondary endpoints were PNIF at 10 minutes, area under the
curve for 12 hours following nasal allergen challenge (AUC12) for
nasal symptoms scores and PNIF, phenotype of cells from nasal
epithelial scrapings and peripheral blood or their secretions, as
well as nasal lavage inflammatory mediator profile. Using total
allergic rhinitis symptom score as the response variable and
treatment, subject and time as explanatory factors, a repeated
measures ANOVA was used to analyse the data including time as
a random effect, also treatment group, baseline score and variables
used in stratification were included as fixed effects. Similar
ANOVA models were used to study the effect of the other
measured response variables against treatment. No adjustments
were made for baseline when no differences were noted between
the four stratified groups in the study. The last number carried
forward procedure was applied where there were missing data or
patients failed to complete the 12 hour collection period.
Laboratory data were analysed using Prism software and a
two-tailed Mann-Whitney non-parametric U-test, without as-
sumption of Gaussian distribution with 95% confidence interval
(CI). Analyses were performed in a blinded fashion.
Results
Patient recruitment and retention
Sixty patients entered the study of which 31 were female. They
had a mean (SD) age of 42.9 (618.6) years, mean body mass index
29.4 (623.6) Kg/m2, mean baseline PNIF105 (644) l/min. Fifty-
five were randomised to receive treatment. They were well
matched for age, gender, smoking status and baseline PNIF (Fig. 1).
Patient demographics can be found in File S1.
Rhinitis Measures at base-line and follow-up
A single-dose nasal allergen challenge was undertaken using the
administration procedure described above. We modified the
method of delivering a single nasal challenge by first determining
each patient’s threshold to allergen in an incremental order to
predict the concentration that would cause a TNSS response of 4.
We achieved a mean TNSS of 3.96 in both groups but the
variance was greater than expected with some patients having a
lower score than this. A minimum of 333 BAU/ml was delivered.
Nasal symptoms and PNIF were recorded at 5, 10 and 30 minutes
then hourly for 12 hours following the challenge. There were no
differences between the two groups for TNSS, PNIF, asthma
symptoms or lung function at any of the time points following the
nasal allergen challenge before or after the intervention period
(Fig. 2).
Laboratory data at base-line
At baseline, there were no discernible differences between
placebo (control) and probiotic (treatment) groups or any of the
stratified groups for any of the parameters evaluated.
Local effects in soluble factors at the nasal mucosa
The magnitude of change at pre- and post-intervention study
periods was measured by subtracting values at baseline (0 hr) from
those derived after nasal allergen challenge (24 hr). This is
described as change from baseline. In nasal lavage, there were
no statistically significant differences between the study groups for
Eotaxin, IL-13, IL-4, IL-5, MIP-1a or RANTES production (data
not shown). Soluble factor receptor release from nasal turbinate
cells was measured by collection of culture supernatants after their
incubation for 48 hours in the absence of any further treatment.
No significant changes were seen in sIL-1RI, sTNFR1, sCD30 or
sIL-4R (data not shown). IL-1b levels differed between the groups
at pre- and post-intervention periods in that the change from
baseline was significant in the control (p#0.0224; 95%CI; range
21.66–4.12 pre- and 24.76–0.86 post-treatment) but not the
treatment group Fig. 3A,B). The mean changes were from
1.2361.40 pg/ml to 21.9561.35 pg/ml in the control group
(Fig. 2A) and from 0.3060.80 pg/ml to21.3361.00 pg/ml in the
treatment group (Fig. 3B) at respective pre- and post-intervention
periods. In contrast, significant change from baseline (p=0.0289)
in the IL-1 decoy receptor sIL-1RII, released from the cell surface
by nasal turbinate cells, was apparent only in the treatment group
with values of 221.97612.08 pg/ml (95%CI range 246.85–2.91)
before and 22.13610.87 pg/ml (95% CI range 20.26–44.52)
after intervention (Fig. 3B). At the same time changes from
baseline in the control group were 231.81620.39 and
12.30611.91 before or after intervention, respectively (Fig. 3A).
Probiotic-Induced Changes at Nasal Mucosa
PLOS ONE | www.plosone.org 3 November 2013 | Volume 8 | Issue 11 | e78650
Local effects in cellular phenotypes at the nasal mucosa
After collection of supernatants from nasal turbinate cells that
had been cultured for 48 hr (described above), cells were collected
and single cell suspensions were prepared. Post-intervention
epithelial cells were identified by their cytokeratin expression
and their CD86 expression compared between control and
treatment groups. Constitutive expression was documented before
nasal allergen challenge at 0 hr when no significant differences
were apparent between control (0.8660.31%) and treatment
(1.0760.41%) groups (Fig. 4A). When responses to allergen were
measured 24 hr after nasal challenge, the control group had
significantly (p=0.0148) fewer CD86+ epithelial cells
(0.0960.31%; 95% Cl range 0.03–0.15) than the treatment
(0.6160.23%; 95%CI range 0.12–1.10) group. Cytokeratin
negative non-epithelial cells that constitutively co-expressed
CD252 with CD86 (CD86+CD252+) comprised 1.5160.49%
and 2.1260.74% in control or treatment groups respectively
(Fig. 4B). After nasal challenge the control group had significantly
(p=0.0347) lower numbers of CD86+CD252+ cells (0.7460.35%;
95%CI range 0.32–1.16) than the treatment (1.7860.19%;
95%CI range 1.05–2.51) group.
Systemic effects in peripheral blood: cytokine release
Peripheral blood mononuclear cells (PBMNC) were isolated and
cultured for 6 days in the presence or absence of pollen allergen.
At the pre-intervention period there were no significant differences
between groups in their change from baseline after nasal challenge
for any of the soluble factors tested apart from IL-8 which has
been excluded from further analysis. After intervention there were
no group-specific differences in the magnitude of change in IL-4,
IL-5, IL-10, IL-12p70, IL-13, MIP-1a Eotaxin, RANTES or
TNF-a production. The supernatants of PBMNC taken 24 hr
after nasal challenge and placed in culture for 6 days gave change
from baseline values in IFN-c secretion of 211.47610.95 pg/ml
for the control group and 47.38639.91 pg/ml for the treatment
group (Fig. 5). Although more IFN-c was produced by the
treatment group, significant difference (p=0.0351) was only
apparent after the same cells were subjected to further in vitro
stimulation with pollen (control 29.29658.78 pg/ml, 95%CI
Figure 1. Patient recruitment and retention. Patient recruitment and retention is described.
doi:10.1371/journal.pone.0078650.g001
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range 213.09–112.30; treatment 76.81637.82 pg/ml, 95%CI
range20.66–154.30). In contrast, a significant (p=0.0283) change
from baseline in TGF-b levels seen in the control group (control
253.306100.30 pg/ml, 95%CI range 25.79–444.38; treatment
34.67647.42 pg/ml, 95%CI range 263.00–132.30) was lost after
additional in vitro stimulation with pollen (control
184.60672.66 pg/ml.; treatment 103.90655.96 pg/ml; Fig. 6).
Systemic effects in peripheral blood: sCD23 release from
the cell surface
As described earlier, isolated PBMNC were cultured for 6 days
in the presence or absence of pollen. No differences were apparent
between the groups before the intervention period (data not
shown). After intervention, in the absence of any challenge
constitutive release of sCD23 was 0.3760.08 U/ml in the control
group and 0.3060.06 U/ml in the treatment group (Fig. 7). Nasal
challenge had little effect, with values of 0.3960.08 U/ml and
0.2560.04 U/ml respectively for control or treatment group. In
vitro addition of pollen to the cultures resulted in significantly
(p=0.0081) more sCD23 release by the control (0.8260.18 U/ml’
95%CI range 0.45–1.20) compared with the treatment
(0.2260.03 U/ml, 95%CI range 0.15–0.30) group. Prior pollen
challenge at the nasal mucosa had little effect on this, with
0.8160.16 U/ml sCD23 shed by the control group and
0.3460.08 U/ml released by the treatment group when the cells
were subjected to both nasal and in vitro challenge.
Serum Immunoglobulins
Next we evaluated levels of IgG, IgG4 and IgE by using
Pharmacia ImmunoCAP 100 system. In contrast to what we
observed during a previous study that involved a natural allergen
exposure [4] no group-specific, statistically significant changes
were detected in pollen-specific total IgG, IgG4 or IgE in serum.
This suggested that a single nasal challenge does not accurately
represent natural allergen exposure which occurs daily, at
variable/lower dose during the pollen season.
Discussion
Here we report that daily oral supplementation with LcS
modified some parameters of allergic inflammation at the nasal
mucosa but this was not paralleled by significant changes of
clinical symptoms of SAR. IL-1b release was significantly lower
(p=,0.05) in nasal lavage fluids of the control group after allergen
challenge while remaining relatively unchanged in the treatment
group. Following nasal challenge, levels of IL-1b normally increase
but return to basal levels within 24 hours through sequestration by
IL-1 responsive cells and normal clearance mechanisms. Interest-
ingly, the treatment group showed a higher level of sIL-1RII. IL-
1RII can act as an anti-inflammatory protein that functions as a
decoy receptor by binding the pro-inflammatory cytokine IL-1
[12] produced by nasal epithelial cells [13]. IL-1 can enhance mast
cell cytokine secretion and histamine release and studies in mice
suggest its contribution to the pathogenesis of allergic rhinitis [14].
Figure 2. Base-line and follow-up measurements. TNSS (A,B) and PNIF (C,D) were recorded at baseline and then at 5, 10 and 30 minutes then
hourly for 12 hours following nasal allergen challenge at pre-intervention (A,C) and post-intervention (B,D) periods.
doi:10.1371/journal.pone.0078650.g002
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IL-1 and IL-1R regulation may therefore be an important
contributory factor to the inflammation that occurs with allergen
exposure [15]. It has been shown that soluble IL-1RII binds IL-1b
to generate a composite binding surface to recruit soluble IL-1
receptor accessory protein (sIL-1RAcP) that serves to increase the
affinity of sIL-1RII for IL-1b [16] while also stabilizing the [IL-
1+IL-1RII] complex [17]. In that case, IL-1 would be prevented
from participating in the proinflammatory response and its kinetics
of degradation would also be altered resulting in its prolonged
detection.
The presence of IL-1b in nasal lavage before allergen challenge
indicates its constitutive production in our allergic subjects, as
described elsewhere [14]. Similarly, CD86+ cells were constitu-
tively present in our nasal mucosal scrapes, possibly through
upregulation by IL-1b [18]. The percentages of CD86+ cells that
we detected at the epithelial mucosa were relatively small, and
lower than those described by others [20], a discrepancy that we
believe can be attributed to the more stringent flow cytometry
gating strategy we adopted. To date, few studies have looked at co-
stimulatory molecules on mucosal surfaces but an investigation
using a single-cell suspension from freshly resected human inferior
nasal turbinates of a healthy individual found only 0.02% of
CD86+ dendritic cells [19], considerably less than were detected in
our study. Viewed in the context of the whole nasal mucosa, small
percentages may represent a sizeable total cell count. Indeed, it is
known that small scale events taking place at the mucosal
interface, such as direct dendritic cell sampling, play a major role
in shaping the local immunological microenvironment [20]. A
lower expression of CD86 in our control group can be explained
by the work of Qureshi and colleagues [21] who show that T cells
Figure 3. Changes in IL-1b and sIL-1RII at the nasal mucosa. Changes from base-line (24 hr–0 hr) in IL-1b levels in nasal lavage (y1 axis) or sIL-
1RII release from nasal epithelial cells (y2 axis) are compared before (pre) and after (post) intervention for control (A) and treatment (B) group;
(*p#0.05). Data are presented as scatter plots showing mean pg/ml with 95% CI.
doi:10.1371/journal.pone.0078650.g003
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typically infiltrate the mucosa during an allergic response. On their
activation, CD86 molecules on the plasma membrane of APCs co-
localize with CTLA-4 on T cells and are then transendocytosed
into the T cells with subsequent loss from the surface of APCs, an
event of clear immunological relevance. Although we did not test
for the presence of T cells or their expression of CTLA-4, a failure
by the treatment group to alter their CD86 expression following
nasal pollen challenge is consistent with the above observations. It
also concurs with the study of Rasche and her colleagues who
found higher CD86 expression after co-stimulation of PBMNC
with allergen plus Lactobacillus [22].
As in Rasche’s study, we observed that the culture supernatants
from in vitro challenged PBMNC had lower levels of sCD23 in the
treatment compared with control group. Due to the multiple forms
of CD23, its many ligands and various activities of the different
complexes, the mechanisms involved in Th2 regulation by CD23
are not fully understood. Although the soluble form of CD23
(sCD23) can both enhance and inhibit Th2-type responses, serum
levels of this molecule are higher in patients suffering from allergic
disorders [23]. A recent study has shown that sCD23 can amplify
Th2 responses and that this effect depends on cleavage of
membrane-bound CD23 from the cell surface [24].
sCD23 has been shown to be regulated by IFN-c and in our
study lower levels of sCD23 in the treatment group were
accompanied by their higher levels of IFN-c, associated with
abated Th2 reactions. This is consistent with findings from in vitro
studies of Roever and colleagues [25] who showed that the
addition of neutralizing anti-IFN-c antibodies increased CD23
expression on B cells stimulated with IL-4 and Birch Pollen
Allergen. In vivo, pre-seasonal use of specific immunotherapy (SIT)
has resulted in a higher frequency of IFN-c-producing cells with
improvement of both symptoms and medication use during the
Figure 4. CD86 expression at the nasal mucosa. After intervention, the percentages of CD86+ Cytokeratin+ epithelial (A) and CD86+ CD252+
non-epithelial (B) cells are compared at baseline between control (C0) and treatment (T0) groups and then again 24 hours after nasal allergen
challenge (C24, T24); (*p#0.05). Data are presented as scatter plots showing mean values with 95% CI.
doi:10.1371/journal.pone.0078650.g004
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pollen season [26]. In addition, a reversal of established Th2
allergic responses has been shown to occur by an IFN-c-dependent
mechanism acting both locally and systemically [27,28].
Studies of oral tolerance and experimental colitis indicate that
reciprocal IFN-c and TGF-b responses regulate the occurrence of
mucosal inflammation [29]. It is also known that TGF-b can
inhibit IFN-c production and vice-versa [30,31]. This would
support the findings of our study where lower TGF-b production
within the treatment group concurred with their higher levels of
IFN-c. In patients with allergic rhinitis, it is known that the
production of TGF-b1 drives airway remodelling and facilitates
on-going inflammation [32]. Evidence has also been provided for
a correlation between TGF-b and higher intraepithelial mast cell
numbers with co-localised TGF-beta receptors, suggesting that the
expression of TGF-b may represent an important biological
process involved in either the recruitment or retention of mast cells
within the epithelium in naturally occurring allergic rhinitis
[33,34,35]. While all of the above point towards a benefit of
Figure 5. Systemic effects on IFN-c production. Systemic effects of intervention are noted in change from baseline (24 hr–0 hr) in IFN-c
production by PBMNC cultured for 6 days in the absence (nasal allergen) or presence (nasal+in vitro allergen) of added pollen; (*p#0.05). Data are
presented as scatter plots showing mean pg/ml with 95% CI.
doi:10.1371/journal.pone.0078650.g005
Figure 6. Systemic effects on TGF-b production. Systemic effects of intervention are noted in change from baseline (24 hr–0 hr) in TGF-b
secretion by 6-day cultures of PBMNC in the absence (nasal allergen) or presence (nasal+in vitro allergen) of added pollen; (*p#0.05). Data are
presented as scatter plots showing mean pg/ml with 95% CI.
doi:10.1371/journal.pone.0078650.g006
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lower TGF-b levels in allergic rhinitis, pollen-specific immuno-
therapy significantly increases serum TGF-b levels that are
correlated with higher IgA synthesis [36], down-regulation of
Th2 responses [37] and prevention of eosinophilia and inflam-
mation [38]. Thus, the regulatory role of TGF-b is both
pleiotropic and complex and the significance of its fluctuating
levels needs to be evaluated in the context of other immunological,
clinical and environmental factors.
Our study shows that the interaction of probiotic organisms
with the intestinal mucosa affects the nasal mucosa. To our
knowledge this is the first time such an event has been
documented. The biological relevance of this finding lies in the
notion that events at mucosal surfaces have a systemic element to
them, as evidenced by changes in blood seen in our study after
nasal allergen challenge and these could influence the ensuing
immune response. Indeed, a single bronchial allergen challenge
with House Dust Mite (HDM) is accompanied by increased levels
of allergen-specific IgE for HDM in serum and an enhanced Th2
response to HDM still detectable 5 weeks after challenge [39].
In our single-dose nasal allergen challenge model we did not
detect any clinically meaningful or statistically significant benefit in
terms of nasal symptoms or nasal inspiratory flow following 16
weeks of probiotic consumption. There were no significant
differences either in asthma symptoms or lung function when
compared with pretreatment measures. In addition to this, our
study did not show any effect in terms of asthma symptoms or lung
function. This result is in keeping with an earlier study with
Lactobacillus species where no effect was noted in clinical outcomes
[40], although our study included a small number of asthmatic
patients all of whom had mild symptoms only. In agreement with
an absence of statistically significant changes in clinical parame-
ters, there were no group-specific differences in the laboratory
analyses of classically allergy-associated components such as IL-4,
IL-5, IL-13, TSLP or pollen-specific Igs, tested either in serum,
nasal lavage, epithelial cell secretions or peripheral blood.
Lack of changes in the clinical symptoms could be explained by
an inability of a single nasal allergen challenge to reproduce the
chronicity of a natural allergen exposure. Although this approach
has the advantage of overcoming the variable nature of pollen
exposure [41], it does not represent a real-life situation where
individuals are exposed to lower concentrations of allergen over a
prolonged period of time. In our study, differences in responses
seen to nasal challenge alone and those following further in vitro
challenge suggests that both allergen dose and multiplicity of
challenge can influence the outcome. The need to find a model
closer to natural allergen exposure has led to the development of
strategies consisting of performing daily challenges with the chosen
allergen and to repeat the process over a few consecutive days.
However, even this does not mimic natural exposure to allergen
since it does not induce lower airway inflammation that is
commonly found in rhinitis subjects naturally exposed to allergen
during the pollen season [42].
We interpreted these data as showing that the interaction of
probiotic organisms with the intestinal mucosa can have effects at
a distant mucosal site, the nasal mucosa and suggest that single
nasal allergen challenges, while permitting control of allergen
exposure, may not replicate natural exposure to allergen.
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